Glaxo gets OK to expand marketing of inhaler drug



Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON (AP) — GlaxoSmithKline plc says it has received U.S. approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.

The expanded approval from the Food and Drug Administration will help Glaxo replace sales of its best-selling product, Advair, which faces generic competition in Europe and pricing pressures in the U.S.

Breo Ellipta was originally approved to treat a form of lung disease. But Thursday's approval expands the drug's use to a much larger patient population of roughly 19 million U.S. adults who have asthma. The inhalable formulation combines two drug ingredients that help open the lung airways: a steroid and a beta agonist.

London-based Glaxo pays royalties on Breo Ellipta to the drug's co-developer Theravance Inc., which is based in San Francisco.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast